Genmab A/S (NASDAQ:GMAB) Stock Sees Unusually High Call Option Buying

Key Points

• Traders bought 24,213 Genmab call options on Thursday—485% above the typical daily volume of 4,137.
• GMAB shares fell 2.8% to $52.35 during Thursday trading, despite reporting quarterly EPS of $0.56, beating the $0.36 consensus estimate; revenue of $1.19 billion came in slightly below expectations.
• Analyst sentiment is broadly positive: 11 of 12 analysts rate the stock Buy or Strong Buy, and the consensus price target is $53.61.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) was the target of unusually large options trading on Thursday. Traders acquired 24,213 call options on the company. This is an increase of 485% compared to the typical daily volume of 4,137 call options.

Hedge Funds Weigh In On Genmab A/S

A number of hedge funds have recently bought and sold shares of the company. First Trust Advisors LP raised its stake in Genmab A/S by 17.0% in the 3rd quarter. First Trust Advisors LP now owns 3,225,639 shares of the company's stock valued at $115,075,000 after acquiring an additional 469,117 shares during the period. Independent Advisor Alliance bought a new stake in shares of Genmab A/S during the 3rd quarter valued at about $150,000. Global Retirement Partners LLC grew its stake in Genmab A/S by 52.8% in the 3rd quarter. Global Retirement Partners LLC now owns 5,607 shares of the company's stock worth $200,000 after buying an additional 1,938 shares in the last quarter. Bessemer Group Inc. increased its stake in Genmab A/S by 38.6% in the third quarter. Bessemer Group Inc. now owns 729 shares of the company's stock valued at $26,000 after acquiring an additional 203 shares during the last quarter. Finally, Hantz Financial Services Inc. raised its holdings in shares of Genmab A/S by 37.2% during the 3rd quarter. Hantz Financial Services Inc. now owns 30,051 shares of the company's stock valued at $1,072,000 after buying an additional 8,146 shares in the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Stock Down 2.8%

GMAB stock traded down $1.51 during mid-day trading on Thursday, reaching $52.35. 3,495,348 shares of the company traded hands, compared to its average volume of 2,558,773. The stock has a market cap of $32.67 billion, a price-to-earnings ratio of 44.75, a P/E/G ratio of 2.18 and a beta of 0.73. The company has a quick ratio of 2.43, a current ratio of 2.45 and a debt-to-equity ratio of 0.74. Genmab A/S has a fifty-two week low of $23.62 and a fifty-two week high of $59.97. The firm's 50 day moving average price is $40.46 and its 200 day moving average price is $31.43.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.36 by $0.20. Genmab A/S had a return on equity of 13.67% and a net margin of 16.97%. The company had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.20 billion. As a group, equities research analysts predict that Genmab A/S will post 1.28 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Morgan Stanley boosted their price objective on Genmab A/S from $42.00 to $57.00 and gave the company an "equal weight" rating in a report on Friday, October 30th. HC Wainwright increased their target price on Genmab A/S from $50.00 to $70.00 and gave the stock a "buy" rating in a report on Thursday, October 29th. Weiss Ratings raised shares of Genmab A/S from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Monday. Truist Financial reissued a "buy" rating and issued a $67.00 price target (up from $45.00) on shares of Genmab A/S in a research report on Thursday, October 29th. Finally, New Street Research set a $43.00 price target on shares of Genmab A/S in a research note on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Genmab A/S has an average rating of "Buy" and a consensus target price of $53.61.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases. The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.